Alois Kolonicny

Title: Alois Kolonicny: Innovator in Antitumor Drug Development

Introduction

Alois Kolonicny is a notable inventor based in Pardubice, Czech Republic. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antitumor compounds. His innovative work has led to the creation of a patent that showcases his expertise in this vital area of research.

Latest Patents

Alois Kolonicny holds a patent for a novel class of compounds, specifically 6-[X-(2-hydroxyethyl)aminoalkyl]-5,11-dioxo-5,6-dihydro-11H-indeno[-1,2-c]isochinoline derivatives. This patent describes the general formula (I), where X represents the number of carbon atoms ranging from 0 to 5 in the aminoalkyl group located on the nitrogen atom in position 6 of the indenoisoquinoline structure. The compounds, along with their salts and derivatives, are particularly effective in treating malignant neoplasias in mammals. The preparation of these compounds involves reacting indeno[1,2-c]isocoumarine with N-(hydroxyethyl)alkylen diamine in a suitable aprotic solvent, such as dimethylformamide, under increased temperature conditions.

Career Highlights

Alois Kolonicny is associated with Vufb A.s., where he has been instrumental in advancing research in the field of pharmaceuticals. His work has not only contributed to the scientific community but has also paved the way for potential therapeutic applications in cancer treatment.

Collaborations

Alois has collaborated with notable colleagues, including Jiri Michalsky and Jiri Hrbata, to further enhance the research and development of innovative drug compounds. Their combined efforts have significantly impacted the field of medicinal chemistry.

Conclusion

Alois Kolonicny's contributions to the development of antitumor drugs highlight his role as a key innovator in the pharmaceutical industry. His patented compounds represent a promising avenue for cancer treatment, showcasing the importance of research and collaboration in advancing medical science.